Clinical Trial: A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07256509) titled 'A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer' on Nov. 20.

Brief Summary: To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.

Study Start Date: Nov. 30

Study Type: INTERVENTIONAL

Condition: Resectable Stage II-IIIB Non-squamous Non-small Cell Lung Cancer With EGFR-sensitizing Mutations (19Del and L858R)

Intervention: DRUG: SYS6010

SYS6010 by intravenous (IV) infusi...